Feb-20-19 08:30AM | Ocular Therapeutix Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD) Business Wire |
Feb-06-19 12:30PM | Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company? Simply Wall St. |
Jan-22-19 07:40AM | Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys What Drives Growth in Today's Competitive Landscape GlobeNewswire |
Jan-11-19 10:32AM | Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza Zacks |
08:38AM | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga |
Jan-10-19 04:01PM | Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire |
Jan-07-19 09:00AM | Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Business Wire |
Dec-28-18 08:00AM | Ocular Therapeutix Announces Completion of Debt Refinancing Business Wire +6.72% |
Dec-26-18 10:56AM | Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
Dec-20-18 11:00AM | Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock? Simply Wall St. |
08:00AM | Ocular Therapeutix Added to Nasdaq Biotechnology Index Business Wire |
Dec-06-18 08:00AM | Ocular Therapeutix Announces the Hiring of Chad Brines, Vice President, Sales Business Wire +8.20% |
Dec-04-18 08:59AM | Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock Zacks |
Dec-03-18 08:23AM | CORRECTING and REPLACING Ocular Therapeutix Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery Business Wire -13.96% |
Nov-21-18 08:00AM | Ocular Therapeutix to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire |
Nov-15-18 06:35PM | H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks SmarterAnalyst +5.95% |
Nov-12-18 07:40AM | Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
Nov-07-18 06:35PM | Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks |
05:36PM | Ocular Therapeutix: 3Q Earnings Snapshot Associated Press |
04:01PM | Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update Business Wire |
Oct-31-18 08:00AM | Ocular Therapeutix To Report Third Quarter 2018 Financial Results Business Wire |
Oct-30-18 10:33AM | Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know Zacks -5.08% |
Oct-22-18 02:54PM | Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst SmarterAnalyst |
Oct-19-18 08:09AM | Ocular Therapeutix stock drops 10% after FDA warning letter MarketWatch |
07:50AM | Ocular Therapeutix Receives FDA Warning Letter Related to ReSure® Sealant Business Wire |
Oct-18-18 08:55AM | Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire |
Oct-11-18 12:57PM | Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. |
Oct-10-18 04:26PM | Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst -5.62% |
Sep-26-18 08:00AM | Ocular Therapeutix to Present at the 2018 Cantor Global Healthcare Conference Business Wire |
Sep-11-18 10:11AM | Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
Sep-10-18 12:36PM | Here's Why Ocular Therapeutix Jumped 21.6% in August Motley Fool |
Aug-29-18 08:00AM | Ocular Therapeutix to Present at the H.C. Wainwright 20th Annual Global Investment Conference Business Wire |
Aug-27-18 08:30AM | Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix New Research Emphasizes Economic Growth GlobeNewswire |
Aug-21-18 07:15PM | Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares GuruFocus.com |
Aug-20-18 01:00PM | JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL) SmarterAnalyst |
Aug-07-18 05:20PM | Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates Zacks |
04:17PM | Ocular Therapeutix: 2Q Earnings Snapshot Associated Press |
04:00PM | Ocular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update Business Wire |
Jul-31-18 04:00PM | Ocular Therapeutix To Report Second Quarter 2018 Financial Results Business Wire |
Jul-19-18 08:00AM | Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA® Business Wire |
05:53AM | Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy? Zacks |
Jul-18-18 07:26AM | Ocular Therapeutix (OCUL) Enters Oversold Territory Zacks |
Jun-29-18 08:00AM | Ocular Therapeutix Announces NDA Resubmission of DEXTENZA Business Wire -6.90% |
Jun-22-18 07:55AM | Report: Developing Opportunities within Mercantile Bank, Kindred Healthcare, Ocular Therapeutix, Roper Technologies, Milacron, and First Defiance Financial Future Expectations, Projections Moving into 2018 GlobeNewswire |
Jun-12-18 08:00AM | Ocular Therapeutix to Present at the 2018 JMP Securities Life Sciences Conference Business Wire +6.34% |
May-29-18 10:24AM | 5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace |
May-14-18 09:52PM | Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents |
May-08-18 05:10PM | Ocular Therapeutix: 1Q Earnings Snapshot Associated Press |
04:01PM | Ocular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Business Wire |
May-03-18 08:38AM | Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension Business Wire |
07:45AM | Investor Expectations to Drive Momentum within Quaker Chemical, Ocular Therapeutix, Viad, Ingredion, LivePerson, and Tableau Software Discovering Underlying Factors of Influence GlobeNewswire |
Apr-27-18 08:00AM | Ocular Therapeutix to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire |
Apr-26-18 04:01PM | Ocular Therapeutix to Report First Quarter 2018 Financial Results Business Wire |
Apr-09-18 04:30PM | Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium Business Wire |
10:29AM | Biotechs Take the Lead This Morning TheStreet.com |
Apr-03-18 03:11PM | Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. |
Mar-22-18 04:36PM | Ocular Therapeutix To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 Business Wire |
06:40AM | Can the Rally in Ocular Therapeutix (OCUL) Shares Continue? Zacks |
Mar-16-18 01:11AM | Edited Transcript of OCUL earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents +9.94% |
Mar-15-18 08:30PM | Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic? Simply Wall St. |
Mar-09-18 08:20AM | Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
Mar-08-18 01:00PM | Under SEC scrutiny, Bedfords Ocular Therapeutix plans FDA do-over American City Business Journals |
09:23AM | Ocular Therapeutix reports 4Q loss Associated Press |
07:30AM | Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update Business Wire |
06:35AM | Want To Invest In Ocular Therapeutix Inc (NASDAQ:OCUL)? Heres How It Performed Lately Simply Wall St. |
Feb-28-18 08:00AM | Ocular Therapeutix to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire |
Feb-27-18 04:00PM | Ocular Therapeutix To Report Fourth Quarter 2017 Financial Results Business Wire |
Feb-21-18 08:02AM | Top 3 Stocks Insiders Are Buying Simply Wall St. +5.85% |
Feb-08-18 08:00AM | Ocular Therapeutix to Participate in the 2018 Glaucoma 360 Meeting in San Francisco Business Wire |
Jan-29-18 04:01PM | Ocular TherapeutixTM Announces Closing of Public Offering of Common Stock Business Wire +6.91% |
Jan-25-18 09:11AM | Benzinga Pro's 4 Stocks To Watch Today Benzinga -14.22% |
09:09AM | Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock Business Wire |
Jan-24-18 04:01PM | Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire |
Jan-08-18 08:20AM | New Research Coverage Highlights TTM Technologies, LogMeIn, Ocular Therapeutix, Everbridge, Power Integrations, and CBIZ Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
08:00AM | Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality Business Wire |
Jan-01-18 09:15AM | Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube |
Dec-26-17 11:55AM | ETFs with exposure to Ocular Therapeutix, Inc. : December 26, 2017 Capital Cube |
Dec-22-17 04:56PM | Ocular Therapeutix gets subpoena from SEC over eye pain drug Reuters |
04:05PM | Ocular Therapeutix Provides Legal Update Business Wire |
Dec-13-17 04:54PM | Is It Too Late To Buy Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. +9.84% |
Dec-05-17 08:00AM | Ocular Therapeutix to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference Business Wire |
Dec-04-17 12:00PM | Was Ocular Therapeutix Incs (OCUL) EPS Decline A Part Of Broader Industry Downturn? Simply Wall St. |
Nov-20-17 08:03PM | Robbins Arroyo LLP Investigates the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire -5.84% |
Nov-13-17 04:05PM | Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents |
Nov-07-17 05:25PM | Ocular Therapeutix reports 3Q loss Associated Press -6.06% |
04:05PM | Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update Business Wire |
12:50PM | Ocular Therapeutix Inc to Host Earnings Call ACCESSWIRE |
Oct-31-17 08:00AM | Ocular Therapeutix to Report Third Quarter 2017 Financial Results Business Wire |
Oct-24-17 07:16PM | Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire +5.73% |
Oct-02-17 02:52PM | How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio? Simply Wall St. |
Sep-26-17 03:09PM | Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire |
Sep-25-17 08:00AM | Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer Business Wire |
Sep-13-17 11:55AM | Have Investors Already Priced In Ocular Therapeutix Incs (OCUL) Growth? Simply Wall St. |
Sep-08-17 09:00AM | Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer Business Wire |
Sep-06-17 04:05PM | Ocular Therapeutix to Present at Three Upcoming Investor Conferences Business Wire |
Sep-05-17 10:35AM | OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017 ACCESSWIRE |
10:33AM | FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017 ACCESSWIRE |
Sep-02-17 09:30AM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL ACCESSWIRE |
Sep-01-17 11:55PM | DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
12:02PM | DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL) ACCESSWIRE |